Potential therapeutic targets for Alzheimer's disease

Expert Opinion on Therapeutic Targets

Volumn 2, Issue 2, 1998, Pages 157-179

  McKeon O'Malley, Catherine ^a   Saunders, Aleister J ^a   Bush, Ashley I ^a   Tanzi, Rudolph E ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0007890460     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2.2.157     Document Type: Article

References (214)

1. KNOPMAN DS, MORRIS JC: An update on primary drug therapies for Alzheimer's disease. Arch. Neurol. (1997) 54:1406-1409. (Pubitemid 27469357)
2. SELKOE DJ: The molecular pathology of Alzheimer's disease. Neuron (1991) 6:487-498.
3. STRUBLE RG,POWERS RE,CASANOVA MFet al.: Neuropeptidergic systems in plaques of Alzheimer's disease. J. Neuropathol. Exp. Neurol. (1987) 46:567-584. (Pubitemid 17129786)
4. KANG J, LEMAIRE HG, UNTERBECK A et al.: The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature (1987) 325:733-736. (Pubitemid 17054046)
5. MILLER DL, PAPAYANNOPOULOS IA, STYLES J et al.: Peptide compositions of the cerebrovascular and senile plaque core amyloid deposits of Alzheimer's disease. Arch. Biochem. Biophys. (1993) 301:41-52. (Pubitemid 23227174)
6. SELKOE DJ: Normal and abnormal biology of the b-amyloid precursor protein. Ann. Rev. Neurosci. (1994) 17:489-517. (Pubitemid 24117040)
7. NAMBA Y, TOMONAGA M, KAWASAKI H, OTOMO E, IKEDA K: Apolipoprotein E immunoreactivity in cerebral deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease. Brain Res. (1991) 541:163-166.
8. ABRAHAM CR, SELKOE DJ, POTTER H: Immunochemical identification of the serine protease inhibitor, a1-antichymotrypsin in the brain amyloid deposits of Alzheimer's disease. Cell (1988) 52:487-501. (Pubitemid 18067514)
9. CORIA F, CASTANO E, LARRONDO-LILLO M et al.: Isolation and characterization of amyloid P component from Alzheimer's disease and other types of cerebral amyloidosis. Lab. Invest. (1988) 58:454-458.
10. GRIFFIN WST, STANLEY LC, LING C et al.: Brain interleukin-1 and the S-100 immunoreactivity are elevated inDownsydrome and Alzheimer's disease. Proc. Natl. Acad. Sci. USA (1989) 86:7611-7615. (Pubitemid 19254506)
11. GOMEZ-PINILLA F, CUMMINGS BJ, COTMAN CW: Induction of basic fibroblast growth factor in Alzheimer's disease pathology. Neuroreport (1990) 1:211-214.
12. BAUER J, STRAUSS S, SCHREITER-GASSER U et al.: Interleukin-6 and alpha-2-macroglobulin indicate an acute-phase state in Alzheimer's disease cortices. FEBS Lett. (1991) 285:111-114.
13. TOOYAMA I, KAWAMATA T, AKIYAMA H et al: Immunohistochemical study of a a2-macroglobulin receptor in Alzheimer and control postmortem human brain. Mol. Chem. Neuropathol. (1993) 18:153-160. (Pubitemid 23129000)
14. SNOW AD, MAR H, HOCHLIN D et al.: The presence of heparan sulfate proteoglycans in the neuritic plaques and congophilic angiopathy in Alzheimer's disease. Am. J. Pathol. (1988) 133:456-463. (Pubitemid 19020577)
15. MCGEER PL, SCHULZER M, MCGEER EG: Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology (1996) 47:425-432. (Pubitemid 26324038)
16. SNOW AD, WIGHT TN: Proteoglycans in the pathogenesis of Alzheimer's disease and other amyloidoses. Neurobiol. Aging (1989) 10:481-497. (Pubitemid 19245453)
17. LOVELL MA, ROBERTSON JD, TEESDALE WJ, CAMPBELL JL, MARKESBERY WR: Copper, iron and zinc in Alzheimer's disease senile plaques. J. Neurosci. Res. (1998) 158:47-52. (Pubitemid 28277534)
18. JOACHIM CL, MORRIS JH, SELKOE DJ: Diffuse senile plaques occur commonly in the cerebellum in Alzheimer's disease. Am. J. Pathol. (1989) 135:309-319. (Pubitemid 19240215)
19. MACKENZIE IRA: Senile plaques do not progressively accumulate with normal aging. Acta Neuropathol. (1994) 87:520-525.
20. WEINGARTEN MD, LOCKWOOD AH, HWO SY, KIRSCHNER MW: A protein factor essential for microtubule assembly. Proc. Natl. Acad. Sci. USA (1975) 72:1858-1862.
21. DRECHSEL DN, HYMAN AA, COBB MH, KIRSCHNER MW: Modulation of the dynamic instability of tubulin assembly by the microtubule-associated protein tau. Mol. Biol. Cell (1992) 3:1141-1154. (Pubitemid 23088964)
22. GRUNDKE-IQBAL I, IQBAL K, TUNG Y et al.: Abnormal phosphorylation of the microtubule-associated protein t (tau) in Alzheimer cytoskeletal pathology. Proc. Natl. Acad. Sci. USA (1986) 83:4913-4917.
23. BRAMBLETT GT, GOEDERT M, JAKES R et al.: Abnormal tau phosphorylation at Ser396 in Alzheimer's disease recapitulates development and contributes to reduced microtubule binding. Neuron (1993) 10:1089-1099. (Pubitemid 23194399)
24. GOEDERT M, TROJANOWSKI JQ, LEE VMY: Tau protein and the neurofibrillary pathology of Alzheimer's disease. In: Mechanisms of Dementia. Wasco W, Tanzi RE (Eds.), Humana Press (1997).
25. BRAAK H, BRAAK E: Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. (Berl.) (1991) 82:239-259.
26. ARRIAGADA PV, GROWDON JH, HEDLEY-WHITE ET, HYMAN BT: Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology (1992) 42:631-639.
27. GOATE A, CHARTIER-HARLIN M,MULLANMet al.: Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature (1991) 349:704-706. (Pubitemid 21912142)
28. MURRELL J, FARLOW M, GHETTI B: A mutation in the amyloid precursor protein associated with hereditary Alzheimer's disease. Science (1991) 254:97-98.
29. CHARTIER-HARLIN M, CRAWFORD F, HOULDEN H: Early-onset Alzheimer's disease caused by mutations at codon 717 of the beta-amyloid precursor protein gene. Nature (1991) 353:844-846. (Pubitemid 21912637)
30. MULLAN M, CRAWFORD F, AXELMAN K et al.: A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of b-amyloid. Nature Genet. (1992) 1:345-347.
31. SHERRINGTON R, ROGAEV EI, LIANG Y et al.: Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature (1995) 375:754-760.
32. LEVY-LAHAD E, WASCO W, POORKAJ P et al.: Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science (1995) 269:973-977.
33. CORDER EH, SAUNDERS AM, STRITTMATTER WJ et al.: Gene dose of apolipoprotein E Type 4 allele and the risk of Alzheimer's disease in late onset families. Science (1993) 261:921-923. (Pubitemid 23275809)
34. BLACKER D, WILCOX MA, LAIRD NM et al.: Alpha-2 macroglobulin is genetically associated with Alzheimer's disease. Nature Genet. (1998) 19:357-360. (Pubitemid 28357907)
35. MOESTRUP SK, GLIEMANN J, PALLESEN G: Distribution of the a2-macroglobulin/low density lipoprotein receptor-related protein in human tissues. Cell Tissue Res. (1992) 269:375-382.
36. KRIEGER M, HERZ J: Structures and functions of multi-ligand lipoprotein receptors: macrophage scavenger receptors and LDL receptor-related protein. Ann. Rev. Biochem. (1994) 63:601-637.
37. KOWAL RC, HERZ J, GOLDSTEIN JL et al.: Low density lipoprotein receptor-related protein mediates uptake of cholesteryl esters derived from apoprotein E-enriched lipoproteins. Proc. Natl. Acad. Sci. USA (1989) 86:5810-5814. (Pubitemid 19217543)
38. KANG DE, SAITOH T, CHEN X et al.: Genetic association of the low density lipoprotein receptor-related protein gene (LRP), an apolipoprotein E receptor, with late-onset Alzheimer's disease. Neurology (1997) 49:56-61. (Pubitemid 27328682)
39. WAVRANT-DEVRIEZE F, PEREZ-TUR J, LAMBERT JC et al.: Association between the low density lipoprotein receptor-related protein (LRP) and Alzheimer's disease. Neurosci. Lett. (1997) 227:68-70. (Pubitemid 27239542)
40. OKUIZUMI K, ONODERA O, NAMBA Y et al.: Genetic association of the very low density lipoprotein (VLDL) receptor gene with sporadic Alzheimer's disease. Nature Genet. (1995) 11:207-209.
41. DAVIS RE, MILLER S, HERRNSTADT C et al.: Mutations in mitochondrial cytochrome c oxidase genes segregate with late-onset Alzheimer's disease. Proc. Natl. Acad. Sci. USA (1997) 94:4526-4531. (Pubitemid 27194275)
42. CLATWORTHY AE, GOMEZ-ISLA T, REBECK GW, WALLACE RB, HYMAN BT: Lack of association of a polymorphism in the low-density lipoprotein receptor-related protein gene with Alzheimer's disease. Arch. Neurol. (1997) 54:1289-1292. (Pubitemid 27452245)
43. PRITCHARD ML, SAUNDERS AM, GASKELL PC et al.: No association between very low density lipoprotein receptor (VLDL-R) and Alzheimer's disease in American caucasians. Neurosci. Lett. (1996) 209:105-108. (Pubitemid 26157798)
44. DAVIS JN, PARKER WDJ: Evidence that two reports of mtDNA cytochrome C oxidase 'mutations' in Alzheimer's disease are based on mDNA pseudogenes of recent evolutionary origin. Biochem. Biophys. Res. Commun. (1998) 244:877-883.
45. POORKAJ P, BIRD TD, WIJSMAN E et al.: Tau is a candidate gene for chromosome 17 frontotemporal dementia. Ann. Neurol. (1998) 43:815-825. (Pubitemid 28280226)
46. HUTTON M, LENDON CL, RIZZU P et al.: Association of missense and 5¢-splice-site mutations in tau with the inherited dementia FTDP-17. Nature (1998) 393:702-705.
47. SPILLANTINI MG, MURRELL JR, GOEDERTMet al.: Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. Proc. Natl. Acad. Sci. USA (1998) 95:7737-7741. (Pubitemid 28293323)
48. SUZUKI N, CHEUNG TT, CAI X et al.: An increased percentage of long amyloid b protein secreted by familial amyloid b protein precursor (bAPP717) mutants. Science (1994) 264:1336-1340.
49. TANZI RE: The molecular genetics of Alzheimer's disease. In: Scientific American: Molecular Neurology. Martin JB (Ed.), Scientific American (1998).
50. ROGAEV EI, SHERRINGTON R, ROGAEVA EA et al.: Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease Type 3 gene. Nature (1995) 376:775-778.
51. BORCHELT DR,THINAKARA NG,ECKMAN Cet al.: Familial Alzheimer's disease-linked presenilin 1 variants elevate Ab1-42/1-40 ratio in vitro and in vivo. Neuron (1996) 17:1005-1013. (Pubitemid 26424026)
52. XIA W, ZHANG J, KHOLODENKO D et al.: Enhanced production and oligomerization of the 42-residue amyloid b-protein by Chinese hamster ovary cells stably expressing mutant presenilins. J. Biol. Chem. (1997) 272:7977-7982. (Pubitemid 27137361)
53. MEHTAN D, REFOLO LM,ECKMAN Cet al.: IncreasedAb42(43) from cell lines expressing presenilin 1 mutations. Ann. Neurol. (1998) 43:256-258. (Pubitemid 28110129)
54. TOMITA T, MARUYAMA K, SAIDO TC et al.: The presenilin 2 mutation (N141I) linked to familial Alzheimer's disease (Volga German families) increases the secretion of amyloid beta protein ending at the 42nd (or 43rd) residue. Proc. Natl. Acad. Sci. USA (1997) 94:2025-2030. (Pubitemid 27113955)
55. MANN DM, IWATSUBO T, CAIRNS NJ et al.: Amyloid beta protein (Abeta) deposition in chromosome 14-linked Alzheimer's disease: predominance of Abeta42(43). Ann. Neurol. (1996) 40:149-156.
56. GOMEZ-ISLA T, WASCO W, PETTINGELL WP et al.: A novel presenilin-1 mutation: increased beta-amyloid and neurofibrillary changes. Ann. Neurol. (1997) 41:809-813. (Pubitemid 27249187)
57. LEMERE CA, LOPERA F, KOSIK KS et al.: The E280A presenilin 1 Alzheimer mutation produces increased A beta 42 deposition and severe cerebellar pathology. Nature Med. (1996) 2:1146-1150. (Pubitemid 26338637)
58. ANCOLIO K, MARAMBAUD P, DAUCH P, CHECLER F: a-Secretase-derived product of b-amyloid precursor protein is decreased by presenilin 1 mutations linked to familial Alheimer's disease. J. Neurochem. (1997) 69:2494-2499. (Pubitemid 27495436)
59. DUFF K,ECKMAN C,ZEHR Cet al.: Increased amyloid-b42(43) in brains of mice expressing presenilin 1. Nature (1996) 383:710-713. (Pubitemid 26360645)
60. SAUNDERS AM, STRITTMATTER WJ, SCHMECHEL DE et al.: Association of apolipoprotein E allele e4 with late-onset familial and sporadic Alzheimer's disease. Neurology (1993) 43:1467-1472. (Pubitemid 23230526)
61. MAHLEY RW: Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science (1988) 240:622-628.
62. ROSES AD, STRITTMATTER WJ, PERICAK-VANCE M et al.: Clinical application of apolipoprotein E genotyping to Alzheimer's disease. Lancet (1994) 343:1564-1565. (Pubitemid 24180058)
63. BULLIDO MJ, ARTIGA MJ, RECUEROMet al.:Apolymorphism in the regulatory region of APOE associated with risk for Alzheimer's dementia. Nature Genet. (1998) 18:69-71. (Pubitemid 28027883)
64. LAMBERT JC, PASQUIER F, COTTEL D et al.: A new polymorphism in the ApoE promoter associated with risk of developing Alzheimer's disease. Hum. Mol. Genet. (1998) 7:533-540. (Pubitemid 28120646)
65. BORTH W: a2-Macroglobulin, a multifunctional binding protein with targeting characteristics. FASEB J. (1992) 6:3345-3353. (Pubitemid 23007099)
66. TANZI RE, GUSELLA JF, WATKINS PC et al.: Amyloid b protein gene: cDNA, mRNA distribution, and genetic linkage near the Alzheimer locus. Science (1987) 235:880-884. (Pubitemid 17019125)
67. WISNIEWSKI T, GHISO J, FRANGIONE B: Alzheimer's disease and soluble Ab. Neurobiol. Aging (1994) 15:143-152.
68. SOLA C, MENGOD G, PROBST A, PALACIOS JM: Differential regional and cellular distribution of b-amyloid precursor protein messenger RNAs containing and lacking the kunitz protease inhibitor domain in the brain of the human, rat and mouse. Neuroscience (1993) 53:267-295. (Pubitemid 23083327)
69. TANZI RE,MCCLATCHEY AI, LAMPERTI ED et al.: Protease inhibitor domain encoded by an amyloid protein precursor mRNA associated with Alzheimer's disease. Nature (1988) 331:528-530. (Pubitemid 18064376)
70. PONTE P, GONZALEZ-DEWHITT P, SCHILLING J: A new A4 amyloid mRNA contains a domain homologous to serine proteinase inhibitors. Nature (1988) 331:525-527. (Pubitemid 18064375)
71. CHEN W-J, GOLDSTEIN JL, BROWN MS: NPXY, a sequence often found in cytoplasmic tails, is required for coated-pit mediated internalization of the low density lipoprotein receptor. J. Biol. Chem. (1990) 265:3116-3123.
72. LAI A, SISODIA SS, TROWBRIDGE IS: Characterization of sorting signals in the beta-amyloid precursor protein cytoplasmic domain. J. Biol. Chem. (1995) 270:3565-3573.
73. WEIDEMAN NA, KONIG G, BUNKE Det al.: Identification, biogenesis, and localization of precursors of Alzheimer's disease A4 protein. Cell (1989) 57:115-126. (Pubitemid 19098873)
74. ESCH FS, KEIM PS, BEATTIE EC et al.: Cleavage of amyloid b peptide during constitutive processing of its precursor. Science (1990) 248:1122-1124.
75. GOLDE TE, ESTUS S,YOUNKIN LH,SELKOE DJ,YOUNKIN SG: Processing of the amyloid protein precursor to potentially amyloidogenic derivatives. Science (1992) 255:728-730.
76. GHISO J, GARDELLA JE, LIEM L, GOREVIC PD, FRANGIONE B: Characterization of a novel processing pathway for Alzheimer's amyloid b precursor protein. Neurosci. Lett. (1994) 171:213-216. (Pubitemid 24142127)
77. SEUBERT P, VIGO-PELFREY C, ESCH FS: Isolation and quantitation of soluble Alzheimer's b-peptide from biological fluids. Nature (1992) 359:325-327.
78. SHOJI M, GOLDE T, GHISO J et al.: Production of the Alzheimer amyloid b protein by normal proteolytic processing. Science (1992) 258:126-129.
79. HAASS C, HUNG AY, SCHLOSSMACHER MG, TEPLOW DB, SELKOE DJ: b-Amyloid peptide and a 3-kDa fragment are derived by distinct cellular mechanisms. J. Biol. Chem. (1993) 268:3021-3024. (Pubitemid 23070917)
80. HAASS C, SCHLOSSMACHER MG, HUNG AY et al.: Amyloid b-peptide is produced by cultured cells during normal metabolism. Nature (1992) 359:322-325.
81. LALOWSKI M, GOLABEK A, LEMERE CA et al.: The 'nonamyloidogenic' p3 fragment (amyloid beta17-42) is a major constituent of Down's syndrome cerebellar preamyloid. J. Biol. Chem. (1996) 271:33623-33631.
82. SPRECHER CA, GRANT FJ, GRIMM G et al.: Molecular cloning of the cDNA for a human amyloid precursor protein homolog: evidence for a multigene family. Biochemistry (1993) 32:4481-4486. (Pubitemid 23143234)
83. WASCO W, GURUBHAGAVATULA S, PARADIS MD et al.: Isolation and characterization of the human APLP2 gene, encoding a homologue of the Alzheimer's associated b protein precursor. Nature Genet. (1993) 5:95-100. (Pubitemid 23261528)
84. SMITH RP, HIGUCHI DA, BROZE GJ: Platelet coagulation Factor XIa-inhibitor, a form of Alzheimer amyloid precursor protein. Science (1990) 248:1126-1128.
85. VAN NOSTRAND WE, SCHMAIER AH, FARROW JS, CUNNINGHAM DD: Protease nexin-II (amyloid b-protein precursor): a platelet a-granule protein. Science (1990) 248:745-748.
86. SAITOH T, SUNDSMO MP, ROCH J et al.: Secreted form of amyloid b protein precursor is involved in the growth regulation of fibroblasts. Cell (1989) 58:615-622. (Pubitemid 19210955)
87. NINOMIYA H, ROCH J, SUNDSMO MP, OTERO DAC, SAITOH T: Amino acid sequence RERMS represents the active domain of amyloid b/A4 protein precursor that promotes fibroblast growth. J. Cell Biol. (1993) 121(4):879-886. (Pubitemid 23143548)
88. CHEN M, YANKNER BA: An antibody to the b amyloid and the amyloid precursor protein inhibits cell-substratum adhesion in many mammalian cell types. Neurosci. Lett. (1991) 125:223-226.
89. BREEN KC, BRUCE M, ANDERTON BH: Beta amyloid precursor protein mediates neuronal cell-cell and cell-surface adhesion. J. Neurosci. Res. (1991) 28:90-100.
90. SCHUBERT D, JIN L-W, SAITOH T,COLEG: The regulation of amyloid b protein precursor secretion and its modulatory role in cell adhesion. Neuron (1989) 3:689-694.
91. GHISO J, ROSTAGNO A, GARDELLA JE et al.: A 109-amino-acid C-terminal fragment of Alzheimer's-disease amyloid precursor protein contains a sequence,-RHDS-, that promotes cell adhesion. Biochem. J. (1992) 288:1053-1059. (Pubitemid 23031794)
92. SMALL DH: A heparin binding domain in the amyloid protein precursor of Alzheimer's disease is involved in the regulation of neurite outgrowth. J. Neurosci. (1994) 14:2117-2127. (Pubitemid 24108121)
93. MILWARD EA, PAPADOPOULOS R, FULLER SJ et al.: The amyloid protein precursor of Alzheimer's disease is a mediator of the effects of nerve growth factor on neurite outgrowth. Neuron (1992) 9:129-137.
94. ARAKI W, KITAGUCHI N, TOKUSHIMA Y et al.: Trophic effect of b-amyloid precursor protein on cerebral cortical neurons in culture. Biochem. Biophys. Res. Commun. (1991) 181:265-271.
95. YAMAMOTO K, MIYOSHI T, YAE T et al.: The survival of rat cerebral cortical neurons in the presence of trophic APP peptides. J. Neurobiol. (1994) 25:585-594. (Pubitemid 24129649)
96. MATTSON MP, CHENG B, CULWELL AR et al.: Evidence for excitoprotective and intraneuronal calcium-regulating roles for secreted forms of the b-amyloid precursor protein. Neuron (1993) 10:243-254. (Pubitemid 23079546)
97. MATTSON MP: Secreted forms of b-amyloid precursor protein modulate dendrite outgrowth and calcium responses to glutamate in cultured embryonic hippocampal neurons. J. Neurobiol. (1994) 25:439-450.
98. NISHIMOTO I, OKAMOTO T, MATSUURA Y et al.: Alzheimer amyloid protein precursor complexes with brain GTP-binding protein Go. Nature (1993) 362:75-79. (Pubitemid 23087295)
99. WHITSON JS, SELKOE DJ, COTMAN CW: Amyloid b protein enhances the survival of hippocampal neurons in vitro. Science (1989) 243:1488-1490. (Pubitemid 19087137)
100. KOWALL NW, MCKEE AC, YANKNER BA, BEAL MF: In vivo neurotoxicity of beta amyloid [b(1-40)] and the b(25-35) fragment. Neurobiol. Aging (1992) 13:537-542.
101. EMRE M, GEULA C, RANSIL BJ, MESULAM M-M: The acute neurotoxicity and effects upon cholinergic axons of intracerebrally injected b-amyloid in the rat brain. Neurobiol. Aging (1992) 13:553-559.
102. RUSH DK, ASCHIMIES S, MERRIMAN MC: Intracerebral b-amyloid (25-35) produces tissue damage: is it neurotoxic? Neurobiol. Aging (1992) 13:591-594.
103. BUSCIGLIO J,LORENZOA,YANKNERBA: Methodological variables in the assessment of beta amyloid neurotoxicity. Neurobiol. Aging (1992) 13:609-612.
104. YANKNER BA: Commentary and perspective on studies of beta amyloid neurotoxicity. Neurobiol. Aging (1992) 13:615-616.
105. PIKE CJ, BURDICK D, WALENCEWICZ AJ, GLABE CG, COTMAN CW: Neurodegeneration induced by b-amyloid peptides in vitro: the role of peptide assembly state. J. Neurosci. (1993) 13(4):1676-1687. (Pubitemid 23095409)
106. LORENZO A, YANKNER BA: Beta-amyloid neurotoxicity requires fibril formation and is inhibited by Congo red. Proc. Natl. Acad. Sci. USA (1994) 91:12243-12247. (Pubitemid 24368641)
107. SCHUBERTD,BEHLC, LESLEYRet al.: Amyloid peptides are toxic via acommonoxidative mechanism. Proc. Natl. Acad. Sci. USA (1995) 92:1989-1993.
108. BEHL C, DAVIS JB, LESLEY R, SCHUBERT D: Hydrogen peroxide mediates amyloid b protein toxicity. Cell (1994) 77:817-827. (Pubitemid 24187680)
109. THOMAS T, THOMAS G, MCLENDON C, SUTTON T, MULLAN M: beta-Amyloid-mediated vasoactivity and vascular endothelial damage. Nature (1996) 380:168-171.
110. BEHL C, DAVIS J, COLE GM, SCHUBERT D: Vitamin E protects nerve cells from amyloid toxicity. Biochem. Biophys. Res. Commun. (1992) 186(2):944-950.
111. YANSD,CHENX,FUJ et al.:RAGEand amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature (1996) 382:685-691.
112. BUSCIGLIO J, YANKNER BA: Apoptosis and increased generation of reactive oxygen species in Down's syndrome neurons in vitro. Nature (1995) 378:776-779. (Pubitemid 26004408)
113. MATTSON MP, CHENG B, DAVIS D et al.: b-amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. J. Neurosci. (1992) 12(2):376-389.
114. JOSEPH R, HAN E: Amyloid b-protein fragment 25-35 causes activation of cytoplasmic calcium in neurons. Biochem. Biophys. Res. Commun. (1992) 184(3):1441-1447.
115. WEISS JH, PIKE CJ, COTMAN CW: Ca+2 channel blockers attenuate b-amyloid peptide toxicity to cortical neurons in culture. J. Neurochem. (1994) 62:372-375.
116. ARISPE N, ROJAS E, POLLARD HB: Alzheimer's disease amyloid b protein forms calcium channels in bilayer membranes: blockade by tromethamine and aluminum. Proc. Natl. Acad. Sci. USA (1993) 90:567-571. (Pubitemid 23028904)
117. KOH J,YANG LL,COTMAN CW:b-amyloid protein increases the vulnerability of cultured cortical neurons to excitotoxic damage. Brain Res. (1990) 533:315-320. (Pubitemid 20377714)
118. QUERFURTH HW, SELKOE DJ: Calcium ionophore increases amyloid b production by cultured cells. Biochemistry (1994) 33:4550-4561. (Pubitemid 24145103)
119. ORRENIUS S, MCCONKEY DJ, BELLOMO G, NICOTERA P: Role of Ca2+ in toxic cell killing. Trends Pharmacol. Sci. (1989) 10:281-285. (Pubitemid 19189749)
120. NICOTERA P, BELLOMO G, ORRENIUS S: Calcium-mediated mechanisms in chemically induced cell death. Ann. Rev. Pharmacol. Toxicol. (1992) 32:449-470.
121. MATTSON MP, ENGLE MG, RYCHLIK B: Effects of elevated intracellular calcium levels on the cytoskeleton and tau in cultured human cortical neurons. Mol. Chem. Neuropathol. (1991) 15:117-142.
122. BUSCIGLIO J, YEH J, YANKNER BA: b-amyloid neurotoxicity in human cortical culture is not mediated by excitotoxins. J. Neurochem. (1993) 61:1565-1568. (Pubitemid 23285123)
123. KALARIA RN: Cerebrovascular degeneration is related to amyloid-b deposition in Alzheimer's disease. Ann. NY Acad. Sci. (1997) 826:263-271. (Pubitemid 27478048)
124. SING CF, DAVIGNON J: Role of the apolipoprotein E polymorphism in determining normal plasma lipid and lipoprotein variation. Am. J. Hum. Genet. (1985) 37:268-285. (Pubitemid 15053161)
125. LEIBSON CL, ROCCA WA, HANSON VA et al.: The risk of dementia among persons with diabetes mellitus. Ann. NY Acad. Sci. (1997) 826:422-427.
126. SKOOG I, NILSSON L, PALMERTZ B, ANDREASSON L, SVANBORG A: A population-based study of dementia in 85-year-olds. New Engl. J. Med. (1993) 328:153-158. (Pubitemid 23021500)
127. SPARKS DL: Coronary artery disease, hypertension, ApoE, and cholesterol: a link to Alzheimer's disease? Ann. NY Acad. Sci. (1997) 826:128-146.
128. KOTILA M,WALTIMOO, NIEMI M-L,LAAKSONENR: Dementia after stroke. Eur. Neurol. (1986) 25:134-140. (Pubitemid 16168636)
129. KNEBL J, DEFAZIO P, CLEARFIELD MB et al.: Plasma lipids and cholesterol esterification in Alzheimer's disease. Mech. Ageing Dev. (1994) 73:69-77. (Pubitemid 24070935)
130. KOUDINOVAR,KOUDINOVANV,BEREZOVTT: Alzheimer's peptidesAbeta 1-40 andA beta 1-28 inhibit the plasma cholesterol esterification rate. Biochem. Mol. Biol. Int. (1996) 38:747-752. (Pubitemid 26258305)
131. NOTKOLA IL, SULKAVA R, PEKKANEN J et al.: Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer's disease. Neuroepidemiology (1998) 17:14-20. (Pubitemid 28153361)
132. SIMONS M, KELLER P, DE STROOPER B et al.: Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc. Natl. Acad. Sci. USA (1998) 95:6460-6464. (Pubitemid 28249035)
133. HOWLAND DS, TRUSKO SP, SAVAGE MJ et al.: Modulation of secreted beta-amyloid precursor protein and amyloid beta-peptide in brain by cholesterol. J. Biol. Chem. (1998) 273:16576-16582. (Pubitemid 28311445)
134. ZHOU Y, RICHARDSON JS: Cholesterol protects PC12 cells from beta-amyloid induced calcium disordering and cytotoxicity. Neuroreport (1996) 7:2487-2490. (Pubitemid 26403002)
135. SUH SW, JENSEN KB, JENSEN MS et al.: Histologic evidence implicating zinc in Alzheimer's disease. Science (1998). Submitted.
136. BUSH AI, PETTINGELL WH, MULTHAUP G et al.: Rapid induction of Alzheimer Ab amyloid formation by zinc. Science (1994) 265:1464-1467. (Pubitemid 24306803)
137. HUANG X, ATWOOD CS, MOIR RD et al.: Zinc-induced Alzheimer's Abeta1-40 aggregation is mediated by conformational factors. J. Biol. Chem. (1997) 272:26464-26470. (Pubitemid 27458865)
138. ATWOOD CS, MOIR RD, HUANG X et al.: Dramatic aggregation of Alzheimer Abeta by Cu(II) is induced by conditions representing physiological acidosis. J. Biol. Chem. (1998) 273:12817-12826. (Pubitemid 28246837)
139. CHERNY RA, LEGG JT, MCLEAN CA et al.: Solubilization of Alzheimer's disease cerebral Ab amyloid deposits by metal chelators. Science (1998). Submitted.
140. BUSH AI, PETTINGELL WH, PARADIS MD, TANZI RE: Modulation of Ab adhesiveness and secretase site cleavage by zinc. J. Biol. Chem. (1994) 269:12152-12158.
141. FREDERICKSON CJ, RAMPY BA, REAMY-RAMPY S, HOWELL GA: Distribution of histochemically reactive zinc in the forebrain of the rat. J. Chem. Neuroanat. (1992) 5:521-530.
142. DANSCHER G: Do the Timm sulphide silver method and the selenium method demonstrate zinc in the brain? In: The Neurobiology of Zinc. Frederickson CJ, Howell GA, Kasarskis EJ (Eds.), Liss (1984).
143. PEREZ-CLAUSELLJ,DANSCHERG: Intravesicular localization of zinc in rat telencephalic boutons: a histochemical study. Brain Res. (1985) 337:91-98. (Pubitemid 15008287)
144. HOWELL GA, WELCH MG, FREDERICKSON CJ: Stimulation-induced uptake and release of zinc in hippocampal slices. Nature (1984) 308:736-738. (Pubitemid 14127671)
145. SLOVITER RS: A selective loss of hippocampal mossy fiber Timm stain accompanies granule cell seizure activity induced by perforant path stimulation. Brain Res. (1985) 330:150-153. (Pubitemid 15143651)
146. TONDER N, JOHANSEN FF, FREDERICKSON CJ, ZIMMER J, DIEMER NH: Possible role of zinc in the selective degeneration of dentate hilar neurons after cerebral ischemia in the adult rat. Neurosci. Lett. (1990) 109:247-252. (Pubitemid 20056964)
147. KOH JY, SUH SW, GWAG BJ et al.: The role of zinc in selective neuronal death after transient global cerebral ischemia. Science (1996) 272:1013-1016. (Pubitemid 26259319)
148. ASSAF SY, CHUNG SH: Release of endogenous Zn2+ from brain tissue during activity. Nature (1984) 308:734-736. (Pubitemid 14127670)
149. SMITH-SWINTOSKY VL, PETTIGREW LC, CRADDOCK SD et al.: Secreted forms of b-amyloid precursor protein protect against ischemic brain injury. J. Neurochem. (1994) 63:781-784.
150. GREENBERG SM, KOO EH, SELKOE DJ, QIU WQ, KOSIK KS: Secreted beta-amyloid precursor protein stimulates mitogen-activated protein kinase and enhances tau phosphorylation. Proc. Natl. Acad. Sci. USA (1994) 91:7104-7108.
151. BARGER SW, HARMON AD: Microglial activation by Alzheimer amyloid precursor protein and modulation by apolipoprotein E. Nature (1997) 388:878-881. (Pubitemid 27377060)
152. FELDERCC,MAAL, BRILEY EM,AXELRODJ: Muscarinic acetylcholine receptor subtypes associated with release of Alzheimer amyloid precursor derivatives activate multiple signal transduction pathways. Ann. NY Acad. Sci. (1993) 695:15-18. (Pubitemid 23348229)
153. HUNG AY, HAASS C, NITSCH RM et al.: Activation of protein kinase C inhibits cellular production of the amyloid beta-protein. J. Biol. Chem. (1993) 268:22959-22962. (Pubitemid 23327996)
154. JACOBSEN JS, SPRUYT MA, BROWN AM et al.: The release of Alzheimer's disease b-amyloid is reduced by phorbol treatment. J. Biol. Chem. (1994) 269:8376-8382. (Pubitemid 24200256)
155. BUXBAUM JD, KOO EH, GREENGARD P: Protein phosphorylation inhibits production of Alzheimer amyloid b/A4 peptide. Proc. Natl. Acad. Sci. USA (1993) 90:9195-9198. (Pubitemid 23306479)
156. GABUZDA D, BUSCIGLIO J, YANKNER BA: Inhibition of b-amyloid production by activation of protein kinase C. J. Neurochem. (1993) 61:2326-2329.
157. BUXBAUM JD, RUEFLI AA,PARKER CA, CYPESS AM,GREENGAR DP: Calcium regulates processing of the Alzheimer amyloid protein precursor in a protein kinase C-independent manner. Proc. Natl. Acad. Sci. USA (1994) 91:4489-4493. (Pubitemid 24143459)
158. NITSCH RM, DENG M, GROWDON JH, WURTMAN RJ: Serotonin 5-HT2a and 5-HT2c receptors stimulate amyloid precursor protein ectodomain secretion. J. Biol. Chem. (1998) 271:4188-4194.
159. JAFFE AB, TORAN-ALLERAND CD, GREENGARD P, GANDY SE: Estrogen regulates metabolism of Alzheimer amyloid beta precursor protein. J. Biol. Chem. (1994) 269:13065-13068. (Pubitemid 24206062)
160. NITSCH RM, DENG A, WURTMAN RJ, GROWDON JH: Metabotropic glutamate receptor subtype mGluR1alpha stimulates the secretion of the amyloid beta-protein precursor ectodomain. J. Neurochem. (1997) 69:704-712. (Pubitemid 27327973)
161. NITSCH RM, KIM C, GROWDON JH: Vasopressin and bradykinin regulate secretory processing of the amyloid protein precursor of Alzheimer's disease. Neurochem. Res. (1998) 23:807-814. (Pubitemid 28173588)
162. BODOVITZ S, KLEIN WL: Cholesterol modulates a-secretase cleavage of amyloid precursor protein. J. Biol. Chem. (1996) 271:4436-4440.
163. NITSCH RM, FARBER SA, GROWDON JH, WURTMAN RJ: Release of amyloid beta-protein precursor derivatives by electrical depolarization of rat hippocampal slices. Proc. Natl. Acad. Sci. USA (1993) 90:5191-5193. (Pubitemid 23183003)
164. DYRKS T, MONNING U, BEYREUTHER K, TURNER J: Amyloid precursor protein secretion and bA4 amyloid generation are not mutually exclusive. FEBS Lett. (1994) 349:210-214. (Pubitemid 24263264)
165. GROWDON JH: Muscarinic agonists in Alzheimer's disease. Life Sci. (1997) 60:993-998. (Pubitemid 27165567)
166. FARBER SA, NITSCH RM, SCHULZ JG, WURTMAN RJ: Regulated secretion of beta-amyloid precursor protein in rat brain. J. Neurosci. (1995) 15:7442-7451. (Pubitemid 3010080)
167. NITSCH RM, SLACK BE, FARBER SA et al.: Receptor-coupled amyloid precursor protein processing. Ann. NY Acad. Sci. (1993) 695:122-127. (Pubitemid 23348248)
168. LEVEY AI: Muscarinic acetylcholine receptor expression in memory
169. ARAUJO DM, LAPCHAK PA, ROBITAILLE Y, GAUTHIER S, QUIRION R: Differential alteration of various cholinergic markers in cortical and subcortical regions of human brain in Alzheimer's disease. J. Neurochem. (1988) 50:1914-1923.
170. RODRIGUEZ-PUERTAS R, PASCUAL J, VILARO T, PAZOS A: Autoradiographic distribution of M1, M2, M3, and M4 muscarinic receptor subtypes in Alzheimer's disease. Synapse (1997) 26:341-350. (Pubitemid 27284105)
171. FLYNN DD, FERRARI-DILEO G, MASH DC, LEVEY AI: Differential regulation of molecular subtypes of muscarinic receptors in Alzheimer's disease. J. Neurochem. (1995) 64:1888-1891.
172. LEBLANCA C,KOUTROUMANI SM,GOODYER CG: Protein kinaseCactivation increases release of secreted amyloid precursor protein without decreasing Abeta production in human primary neuron cultures. J. Neurosci. (1998) 18:2907-2913. (Pubitemid 28163220)
173. FISHER A, HELDMAN E, GURWITZ D et al.: Selective signaling via novel muscarinic agonists: implications for Alzheimer's disease treatments and clinical update. Third Springfield International Symposium on Alzheimer's Disease. Springfield, IL, USA (1994).
174. BODICK NC, OFFEN WW, SHANNON HE et al.: The selective muscarinic agonist xanomeline improves both the cognitive deficits and behavioral symptoms of Alzheimer's disease. Alzheimer's Dis. Assoc. Disord. (1997) 11(Suppl. 4):S16-S22. (Pubitemid 27453885)
175. YAMAGUCHI H, HIRAI S, MORIMATSU M, SHOJI M, NAKAZATO Y: Diffuse type of senile plaques in the cerebellum of Alzheimer-type dementia demonstrated by beta protein immunostain. Acta Neuropathol. (Berl.) (1989) 77:314-319. (Pubitemid 19044199)
176. KIRSCHNER DA, INOUYE H, DUFFY LK et al.: Synthetic peptide homologous to beta protein from Alzheimer's disease forms amyloid-like fibrils in vitro. Proc. Natl. Acad. Sci. USA (1987) 84:6953-6957.
177. TJERNBERGLO,NASLUNDJ, LINDQVIST F et al.: Arrest of b-amyloid fibril formation by a pentapeptide ligand. J. Biol. Chem. (1996) 271:8545-8548. (Pubitemid 26123269)
178. LEVY E, CARMAN MD, FERNANDEZ-MADRID IJ et al.: Mutation of the Alzheimer's disease amyloid gene in hereditary cerebral hemorrhage, Dutch-type. Science (1990) 248:1124-1126.
179. FRASER PE, NGUYEN JT, INOUYE H et al.: Fibril formation by primate, rodent, and dutch-hemorrhagic analogues of Alzheimer amyloid b-protein. Biochemistry (1992) 31:10716-10723.
180. BURDICK D, SOREGHAN B, KWON M et al.: Assembly and aggregation properties of synthetic Alzheimer's A4/beta amyloid peptide analogs. J. Biol. Chem. (1992) 267:546-554.
181. BARROW CJ, ZAGORSKI MG: Solution structures of b peptide and its constituent fragments: relation to amyloid deposition. Science (1991) 253:179-182. (Pubitemid 21917135)
182. FRASER PE, NGUYEN JT, SUREWICZ WK, KIRSCHNER DA: pH-dependent structural transitions of Alzheimer amyloid peptides. Biophys. J. (1991) 60:1190-1201.
183. JARRETT JT, LANSBURY PT, Jr.: Seeding 'one-dimensional crystallization' of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie? Cell (1993) 73:1055-1058. (Pubitemid 23180480)
184. JARRETT JT, LANSBURY PT, Jr.: Amyloid fibril formation requires a chemically discriminating nucleation event: studies of an amyloidogenic sequence from the bacterial protein OsmB. Biochemistry (1992) 31:12345-12352. (Pubitemid 23163109)
185. HILBICH C, KISTERS-WOIKE B, REED J, MASTERS CL, BEYREUTHER K: Substitutions of hydrophobic amino acids reduce the amyloidogenicity of Alzheimer's disease bA4 peptides. J. Mol. Biol. (1992) 228:460-473. (Pubitemid 23007569)
186. GUPTA-BANSAL R, FREDERICKSON RC, BRUNDEN KR: Proteoglycan-mediated inhibition of A beta proteolysis. A potential cause of senile plaque accumulation. J. Biol. Chem. (1995) 270:18666-18671.
187. CASTILLO GM, NGO C, CUMMINGS J, WIGHT TN, SNOW AD: Perlecan binds to the beta-amyloid proteins (A beta) of Alzheimer's disease, accelerates A beta fibril formation, and maintains A beta fibril stability. J. Neurochem. (1997) 69:2452-2465. (Pubitemid 27495432)
188. WATSON DJ,LANDERA D,SELKOE DJ: Heparin-binding properties of the amyloidogenic peptides Abeta and amylin. Dependence on aggregation state and inhibition by Congo red. J. Biol. Chem. (1997) 272:31617-31624.
189. LEVEUGLE B, DING W, LAURENCE F et al.: Heparin oligosaccharides that pass the blood-brain barrier inhibit beta-amyloid precursor protein secretion and heparin binding to beta-amyloid peptide. J. Neurochem. (1998) 70:736-744. (Pubitemid 28079364)
190. GUPTA-BANSAL R, BRUNDEN KR: Congo red inhibits proteoglycan and serum amyloid P binding to amyloid beta fibrils. J. Neurochem. (1998) 70:292-298. (Pubitemid 28020855)
191. REITER RJ, TAN D-X, POEGGELER B et al.: Melatonin as a free radical scavenger: implications for aging and age-related diseases. Ann. NY Acad. Sci. (1998) 719:1-12. (Pubitemid 24199963)
192. TAN D-X,CHEN L-D, POEGGELER B,MANCHESTER LC, REITER RJ: Melatonin: a potent, endogenous hydroxyl radical scavenger. Endocr. J. (1993) 1:57-60.
193. TAN D-X, POEGGELER B, REITER RJ et al.: The pineal hormone melatonin inhibits DNA adduct formation induced by the chemical carcinogen safrole in vivo. Cancer Lett. (1993) 70:65-71. (Pubitemid 23219861)
194. REITER RJ, RICHARDSON BA, JOHNSON CY, FERGUSON BN, DINH DT: Pineal melatonin rhythm: reduction in aging Syrian hamsters. Science (1980) 210:1372-1373. (Pubitemid 11175499)
195. DORI D, CASALE G, SOLERTE SB et al.: Chrono-neuroendocrinological aspects of physiological aging and senile dementia. Chronobiologia (1994) 21:121-126. (Pubitemid 24165064)
196. PAPPOLLA M, SOS M, OMAR RA et al.: Melatonin prevents death of neuroblastoma cells exposed to the Alzheimer amyloid peptide. J. Neurosci. (1997) 17:1683-1690. (Pubitemid 27089813)
197. PAPPOLLA M, BOZNER P, SOTO C et al.: Inhibition of Alzheimer beta-fibrillogenesis by melatonin. J. Biol. Chem. (1998) 273:7185-7188.
198. DANIELS WM, VAN RENSBURG SJ, VAN ZYL JM, TALJAARD JJ: Melatonin prevents beta-amyloid-induced lipid peroxidation. J. Pineal Res. (1998) 24:78-82. (Pubitemid 28168318)
199. MCDERMOTT JR, GIBSON AM: Degradation of Alzheimer's beta-amyloid protein by human and rat brain peptidases: involvement of insulin-degrading enzyme. Neurochem. Res. (1997) 22:49-56.
200. MCDERMOTT JR, GIBSON AM: Degradation of Alzheimer's beta-amyloid protein by human cathepsin D. Neuroreport (1996) 7:2163-2166. (Pubitemid 26361838)
201. HAMAZAKI H: Cathepsin D is involved in the clearance of Alzheimer's beta-amyloid. FEBS Lett. (1996) 396:139-142. (Pubitemid 26377812)
202. MENTLEI NR,LUDWIG R,MARTENSEN I: Proteolytic degradation of Alzheimer's disease amyloid b-peptide by a metalloproteinase from microglia cells. J. Neurochem. (1998) 70:721-726. (Pubitemid 28079362)
203. PARESCE DM, GHOSH RN, MAXFIELD FR: Microglial cells internalize aggregates of the Alzheimer's disease amyloid beta-protein via a scavenger receptor. Neuron (1996) 17:553-565. (Pubitemid 26322226)
204. QIU WQ, BORTH W, YE Z et al.: Degradation of amyloid b-protein by a serine protease-a2-macroglobulin complex. J. Biol. Chem. (1996) 271:8443-8451. (Pubitemid 26108682)
205. COLE GM, BELL L, TRUONG QB, SAITOH T: An endosomal-lysosomal pathway for degradation of amyloid precursor protein. Ann. NY Acad. Sci. (1992) 674:103-117. (Pubitemid 23077399)
206. MCGEER PL, MCGEER EG: Chronic inflammatory mechanisms of the brain: implications for the treatment of Alzheimer's disease. Dementia (1995) 9:111-123.
207. JENKINSON ML, BLISS MR, BRAIN AT, SCOTT DL: Rheumatoid arthritis and senile dementia of the Alzheimer's type. Br. J. Rheumatol. (1989) 28:86-88.
208. MCGEER PL, MCGEER EG, ROGERS J, SIBLEY J: Anti-inflammatory drugs and Alzheimer's disease. Lancet (1990) 335:1037.
209. BREITNER JCS: The role of anti-inflammatory drugs in the prevention and treatment of Alzheimer's disease. Ann. Rev. Med. (1996) 47:401-411. (Pubitemid 26138900)
210. HAYNES RC: Adrenocorticotropic hormone; adrenocortical steroids and their synthetic analogs; inhibitors of the synthesis and the actions of adrenocortical hormones. In: The Pharmacological Basis of Therapeutics. Gilman AG, Rall TW, Nies AS, Taylor P (Eds.), Pergamon Press (1990).
211. SOLL AH, WEINSTEIN WM, KURATA J, MCCARTHY D: Nonsteroidal anti-inflammatory drugs and peptic ulcer disease. Ann. Intern. Med. (1991) 114:307-319.
212. GOEDERT M, JAKES R, SPILLANTINI MG et al.: Assembly of microtubule-associated protein tau into Alzheimer-like filaments induced by sulphated glycosaminoglycans. Nature (1996) 383:550-553. (Pubitemid 26346185)
213. GOEDERT M, SPILLANTINI MG, HASEGAWA M et al.: Molecular dissection of the neurofibrillary lesions of Alzheimer's disease. Cold Spring Harbor Symp. Quant. Biol. (1998) 61:565-573.
214. HASEGAWA M, CROWTHER RA, JAKES R, GOEDERT M: Alzheimer-like changes in microtubule-associated protein tau induced by sulfated glycosaminoglycans. Inhibition of microtubule binding, stimulation of phosphorylation, and filament assembly depend on the degree of sulfation. J. Biol. Chem. (1997) 272:33118-33124. (Pubitemid 28023655)